Therapeutic Response

EGFR activating variants status confers therapeutic sensitivity to Afatinib in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Afatinib Monotherapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved afatinib for reimbursement as a monotherapy treatment option for the treatment of EGFR TKI-naive adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbor activating EGFR mutation(s), as demonstrated by a validated test method.
Giotrif (afatinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized afatinib as a monotherapy indicated for the treatment of EGFR TKI-naive adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR variants.